LIGAND PHARMACEUTICAL ($LGND) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of $2.02 per share, beating estimates of $1.59 by $0.43. The company also reported revenue of $59,670,000, beating estimates of $56,700,667 by $2,969,333.
You can see Quiver Quantitative's $LGND stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LIGAND PHARMACEUTICAL Insider Trading Activity
LIGAND PHARMACEUTICAL insiders have traded $LGND stock on the open market 36 times in the past 6 months. Of those trades, 0 have been purchases and 36 have been sales.
Here’s a breakdown of recent trading of $LGND stock by insiders over the last 6 months:
- JASON ARYEH has made 0 purchases and 3 sales selling 10,000 shares for an estimated $1,708,087.
- NANCY RYAN GRAY has made 0 purchases and 2 sales selling 6,571 shares for an estimated $1,350,011.
- JOHN L LAMATTINA has made 0 purchases and 2 sales selling 4,179 shares for an estimated $858,575.
- JOHN W KOZARICH has made 0 purchases and 28 sales selling 2,802 shares for an estimated $520,273.
- OCTAVIO ESPINOZA (Chief Financial Officer) sold 1,804 shares for an estimated $339,711
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
LIGAND PHARMACEUTICAL Hedge Fund Activity
We have seen 170 institutional investors add shares of LIGAND PHARMACEUTICAL stock to their portfolio, and 162 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,142,820 shares (-75.9%) from their portfolio in Q4 2025, for an estimated $216,072,977
- MACQUARIE GROUP LTD removed 751,788 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $142,140,557
- ACUITAS INVESTMENTS, LLC removed 402,494 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $76,099,540
- FRANKLIN RESOURCES INC added 266,304 shares (+115.9%) to their portfolio in Q4 2025, for an estimated $50,350,097
- CONGRESS ASSET MANAGEMENT CO removed 187,248 shares (-28.1%) from their portfolio in Q4 2025, for an estimated $35,402,979
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 146,311 shares (+385028.9%) to their portfolio in Q4 2025, for an estimated $27,663,020
- INVESCO LTD. added 138,169 shares (+36.5%) to their portfolio in Q4 2025, for an estimated $26,123,612
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
LIGAND PHARMACEUTICAL Congressional Stock Trading
Members of Congress have traded $LGND stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LGND stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 01/15, 01/05 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
LIGAND PHARMACEUTICAL Analyst Ratings
Wall Street analysts have issued reports on $LGND in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/10/2025
- Citigroup issued a "Buy" rating on 12/09/2025
- Benchmark issued a "Buy" rating on 11/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
- Oppenheimer issued a "Outperform" rating on 09/03/2025
To track analyst ratings and price targets for LIGAND PHARMACEUTICAL, check out Quiver Quantitative's $LGND forecast page.
LIGAND PHARMACEUTICAL Price Targets
Multiple analysts have issued price targets for $LGND recently. We have seen 6 analysts offer price targets for $LGND in the last 6 months, with a median target of $237.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $239.0 on 02/24/2026
- Annabel Samimy from Stifel set a target price of $230.0 on 12/10/2025
- Douglas Miehm from RBC Capital set a target price of $235.0 on 12/10/2025
- Yigal Nochomovitz from Citigroup set a target price of $270.0 on 12/09/2025
- Robert Wasserman from Benchmark set a target price of $220.0 on 11/07/2025
- Trevor Allred from Oppenheimer set a target price of $250.0 on 11/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
